A Phase 2, Randomized Study to Evaluate Safety, Efficacy, and Optimal Dose of ABBV-400 in Combination with Fluorouracil, Folinic Acid, and Bevacizumab and to Evaluate Safety and Efficacy of ABBV-400 in Combination with Bevacizumab in Previously Treated Subjects with Unresectable Metastatic Colorectal Cancer

Sponsor:

AbbVie, Inc

Sponsor Study ID:

M24-311

CTO #:

103945

NCT Number:

NCT06107413

Phase:

II

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Colon

Study Objectives:

To optimize ABBV-400 dose in combination with 5-FU, folinic acid, and bevacizumab to determine the RP3D regimen for the combination. To evaluate the efficacy as measured by OR and PFS of ABBV-400 in combination with 5-FU, folinic acid, and bevacizumab, To evaluate the safety and tolerability of ABBV-400 in combination with 5-FU, folinic acid, and bevacizumab.

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)